Chronic ocular surface diseases affect between 15-20% of the global population. For most of these chronic ailments, there are no long-term treatments, no FDA-approved protocols while exiting antibiotics or steroids can not be used continuously without significant side effects.
Our mission is to unlock and exploit the potential of cannabinoid-based medicines, in order to address serious conditions, that currently have limited or no treatment options. In order to provide an effective solution to ocular issues, 3R Pharma is developing a patented ocular treatment method using cannabinoid-based formulations.
We aim to provide efficient ocular treatment formulations and procedures for various eye conditions such as blepharitis, meibomian gland disfunction and evaporative dry eye.
MGD Meibomian Gland Disfunction
The Meibomian glands play a crucial role in the maintaining a healthy ocular surface. Located in the upper and lower eyelids, these oil-producing glands are are responsible for secreting the lipid layer (meibum) that forms the outermost layer of the tear film, which lubricates the ocular surface during blinking and protects against tear evaporation.
Meibomian gland dysfunction (MGD) is the leading cause of dry eye disease (DED). Reduced secretion of lipids due to MGD leads to instability of the tear film and drying of the ocular surface, resulting in damage and the signs and symptoms of DED and other conditions of the eye. In fact, clinical signs of obstructive MGD – characterized by reduced secretion and alterations in the physical properties of meibum – are present in 86% of people with DED.
What is blepharitis?
Blepharitis is chronic inflammation of the eyelids that commonly affects the lash-bearing region of the eyelids. It is associated with overgrowth of bacterial (typically staphylococcus) and/or sebaceous gland activity, or posterior blepharitis, which affects the meibomian glands. Posterior blepharitis can be related to seborrhea, gland obstruction, or a mix of the two. There is also considerable overlap between anterior and posterior blepharitis and patients may present with both forms concurrently.
What are the symptoms of blepharitis?
Posterior blepharitis may be asymptomatic in its mildest form, but it can also be a major source of chronic irritation and inflammation of the eyelids in more severe cases. Symptoms affecting the eyelids can arise from local inflammation and release of inflammatory mediators, as well as dilatation of the Meibomian gland ducts.
How prevalent is blepharitis?
Reliable estimates of the prevalence and incidence of blepharitis are lacking, despite the fact that it is one of the most common disorders encountered in eye care practice. According to estimates from eye care specialists, blepharitis is seen in clinical practice in 37% to 47% of patients. The prevalence is rising with age and in US alone it is estimated that 80 million people suffer from blepharitis.
Is there a treatment for blepharitis?
There is currently no long-term cure for blepharitis, with the exception of cases that result from a staphylococci infection. Rather than treat the disease itself, most clinicians manage the disease and its symptoms using eyelid hygiene management such as: warm compresses and eyelid scrubs as well as topical or systemic antibiotics, topical steroids, and artificial tears.